180 related articles for article (PubMed ID: 12433797)
1. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions.
Yuan R; Madani S; Wei XX; Reynolds K; Huang SM
Drug Metab Dispos; 2002 Dec; 30(12):1311-9. PubMed ID: 12433797
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Löfgren S; Hagbjörk AL; Ekman S; Fransson-Steen R; Terelius Y
Xenobiotica; 2004 Sep; 34(9):811-34. PubMed ID: 15742976
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation.
Peng Y; Wu H; Zhang X; Zhang F; Qi H; Zhong Y; Wang Y; Sang H; Wang G; Sun J
Xenobiotica; 2015; 45(11):961-77. PubMed ID: 26007223
[TBL] [Abstract][Full Text] [Related]
7. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841
[TBL] [Abstract][Full Text] [Related]
8. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
9. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
[TBL] [Abstract][Full Text] [Related]
12. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.
Zhang W; Ramamoorthy Y; Tyndale RF; Sellers EM
Drug Metab Dispos; 2003 Jun; 31(6):768-72. PubMed ID: 12756210
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochromes P450 by antifungal imidazole derivatives.
Zhang W; Ramamoorthy Y; Kilicarslan T; Nolte H; Tyndale RF; Sellers EM
Drug Metab Dispos; 2002 Mar; 30(3):314-8. PubMed ID: 11854151
[TBL] [Abstract][Full Text] [Related]
14. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation.
Easterbrook J; Fackett D; Li AP
Chem Biol Interact; 2001 May; 134(3):243-9. PubMed ID: 11336973
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
16. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
17. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.
Pearce RE; McIntyre CJ; Madan A; Sanzgiri U; Draper AJ; Bullock PL; Cook DC; Burton LA; Latham J; Nevins C; Parkinson A
Arch Biochem Biophys; 1996 Jul; 331(2):145-69. PubMed ID: 8660694
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.
Kim MJ; Kim H; Cha IJ; Park JS; Shon JH; Liu KH; Shin JG
Rapid Commun Mass Spectrom; 2005; 19(18):2651-8. PubMed ID: 16124035
[TBL] [Abstract][Full Text] [Related]
19. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
20. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.
Liu KH; Lee YM; Shon JH; Kim MJ; Lee SS; Yoon YR; Cha IJ; Shin JG
Xenobiotica; 2004 May; 34(5):429-38. PubMed ID: 15370959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
